56
Participants
Start Date
August 31, 2007
Primary Completion Date
June 30, 2011
Study Completion Date
June 30, 2011
TAK-285 Dose Escalation Cohorts
TAK-285 50 mg tablet, orally, once or twice daily for three weeks, followed by seven days off. Dose escalation to maximum tolerated dose, with possibility of continuous dosing per cycle (daily dosing for four weeks without a break between cycles).
TAK-285 Recommended Phase 2 Dosing Cohort
Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.
University of Maryland Greenbaum Cancer Center, Baltimore
Indiana University Cancer Center, Indianapolis
Karmanos Cancer Center, Detroit
Lead Sponsor
Millennium Pharmaceuticals, Inc.
INDUSTRY